Analyst Research Report Snapshot

Title:

GW PHARMACEUTICALS - AWAITING SATIVEX APPROVAL

Price:

$10.00

Provider:

Edison Investment Research

Date:

26 Nov 2009

Pages:

8

Type:

AcrobatPDF

Companies referenced:

GWP.L

Available for Immediate Download
Summary:

GW Pharmaceuticals’ investment case remains highly geared to the potential forthcoming EU approval of Sativex, which is expected in H1 next year. This would clearly be a significant milestone for the company and triggers the payment of £12.5m in cash from licensees Bayer and Almirall. These payments in turn should provide GW with a solid financial platform from which to expand its own R&D efforts. FOR MORE INFORMATION ON THE ATTACHED RESEARCH PLEASE CALL 020 3077 5700, EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.